| US stocks edge higher following the latest U-turn for oil prices |
AP Online |
05/21 |
17:08 |
| Equus Announces First Quarter Net Asset Value |
Globe Newswire |
05/21 |
17:07 |
| ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES |
Globe Newswire |
05/21 |
17:06 |
| Whale Dynamic Joins Hitch Open World AI Championships as Official Mapping Technology Partner, Delivering Centimeter-Accurate HD Map of Tianmen Mountain for 2026 Racing Season |
Globe Newswire |
05/21 |
17:06 |
| Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026 |
Globe Newswire |
05/21 |
17:05 |
| Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology |
Globe Newswire |
05/21 |
17:05 |
| Imperial Announces Voting Results for the Election of Directors |
Globe Newswire |
05/21 |
17:02 |
| Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin |
Globe Newswire |
05/21 |
17:02 |
| Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis |
Globe Newswire |
05/21 |
17:01 |
| Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data |
Globe Newswire |
05/21 |
17:01 |
| Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models |
Globe Newswire |
05/21 |
17:01 |
| ALDX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX |
Globe Newswire |
05/21 |
17:01 |
| AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit |
Globe Newswire |
05/21 |
17:00 |
| Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting |
Globe Newswire |
05/21 |
17:00 |
| HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting |
Globe Newswire |
05/21 |
17:00 |
| Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting |
Globe Newswire |
05/21 |
17:00 |
| BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting |
Globe Newswire |
05/21 |
17:00 |
| Legend Biotech Announces Presentations at ASCO 2026 |
Globe Newswire |
05/21 |
17:00 |
| Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline |
Globe Newswire |
05/21 |
17:00 |
| Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy |
Globe Newswire |
05/21 |
17:00 |
| Zodiac Partners II, LLC Provides an Update to its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash |
Globe Newswire |
05/21 |
17:00 |
| TruGolf Reports First Quarter 2026 Results |
Globe Newswire |
05/21 |
17:00 |
| Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC |
Globe Newswire |
05/21 |
17:00 |
| Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting |
Globe Newswire |
05/21 |
17:00 |
| The Math Underlying the Success of Tort Reforms – Florida Property Insurance and Beyond |
Globe Newswire |
05/21 |
16:45 |
